ABIRISK announcements
-
Organized under the flag of ABIRISK and the European Immunogenicity Platform (EIP), a central meeting place for European biopharmaceutical companies and scientific experts active in the field
of immunogenicity.
Download the flayer
For no ABIRISK members: the registration opens 15 June 2017 on the EIP website -
Congratulations to Laura Magill who has been chosen as the winner of the ‘Young Investigator Award 2017’ by the British Society for Rheumatology. Laura, a PhD student at UCL, is involved in the immunophenotyping of Rheumatoid Arthritis patients, which forms part of ABIRISK. She’ll be giving a talk on this data at the British Society of Rheumatology meeting in April.
-
Download the publication:
Link J, Ramanujam R, Auer M et al.
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: a descriptive study of test results.
PLoS One. 2017 Feb 7;12(2):e0170395.
-
Download the publication:
Bachelet D, Hässler C, Mbogning J et al.
Occurrence of anti-drug antibodies against interferon-beta and natalizumab in multiple sclerosis: A collaborative cohort analysis.
PLoS One. 2016 Nov 2;11(11):e0162752.
-
Download the publication:
Vultaggio A, Petroni G, Pratesi S et al.
Circulating T cells to infliximab are mainly detectable in treated patients developing anti-drug antibodies and hypersensitivity reactions.
Clin Exp Immunol. 2016 Dec;186(3):364-372. doi: 10.1111/cei.12858.
-
The April 2018 issue of IMI Newsletter is online
Read it on the IMI website
-
Forthcoming international conferences
Open the updated list
